

<b>Supplementary Information Disclosure Statement</b>  <b>List of references cited by Applicant</b>  (Sheet 1 of 1)	Attorney Docket Number <b>Fujii-8</b>	Application Number <b>10/525,838</b>
	Applicant: Nobutaka FUJII et al.	
	Filing Date <b>February 25, 2005</b>	Group Art Unit <b>1654</b>

U.S. PATENT DOCUMENTS							
*Examiner Initial		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1						

FOREIGN PATENT DOCUMENTS								
*Examiner Initial		DOCUMENT NUMBER	ISSUE DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1	WO 95/10534	April 20, 1995	WO	A61K	38/00	YES	
	B2	WO 99/47158	September 23, 1999	WO	A61K	38/00	YES	
	B3	WO 01/38352	May 31, 2001	WO	C07K	16/24	YES	
	B4	WO 01/85196	November 15, 2001	WO	A61K	38/00	YES	

*Examiner Initial	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	C1	Hatse <i>et al.</i> , CXC-chemokine receptor 4 as a potential new therapeutic target for neuroblastoma and breast cancer. <i>International Journal of Canc. Suppl.</i> 2002;13:349.
	C2	Hiramatsu <i>et al.</i> , Synthesis of CXCR4 antagonists, T140 derivatives with improved biostability, and their SAR study. <i>Peptide Science</i> 203;2002: 213-216 (Yamada, T, ed.).
	C3	Mori <i>et al.</i> , Involvement of Stromal cell-Derived Factor 1 and CXCR4 receptor system in pancreatic cancer. <i>Gastroenterology</i> , 2002;122(4), <i>Suppl 1</i> :A490. (Abstract T1608)
	C4	Tamamura <i>et al.</i> , Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure. <i>Bioorg Med Chem.</i> 1998, 6:473-9.
	C5	Tamamura <i>et al.</i> , T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer". <i>FEBS Lett.</i> 2003 (Aug 28) 550:79-83.
EXAMINER		DATE CONSIDERED